Hypertonic Saline for PCD Lung Clearance
Part of Ear, nose & throat, Genetic & congenital, Lungs & breathing clinical trials.
This study tests an inhaled medication (hypertonic saline) to see if it helps clear mucus from the lungs of people with Primary Ciliary Dyskinesia (PCD). It involves exercise testing and regular lung function checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of Primary Ciliary Dyskinesia (PCD) through genetic testing.
- Your lung function (FEV1) must be greater than 30% of what's expected for someone your age and size.
- You must be able to exercise for 20 minutes during a screening test.
- You cannot have coughed up a significant amount of blood (more than 2 tablespoons) in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the airways in people with primary ciliary dyskinesia (PCD) react to certain triggers. It aims to understand if these airways are more sensitive, which could help improve treatment for breathing problems.
This trial tests whether a stay at a thermal spa can improve symptoms of Primary Ciliary Dyskinesia (PCD), a genetic lung condition. It's for adults with stable PCD who haven't had a recent infection or spa treatment.
This study tests whether a breathing test called nasal nitric oxide can help improve care for people with primary ciliary dyskinesia (PCD) or related lung/sinus problems. The goal is to see if the test can better guide diagnosis and treatment planning.
This study looks at how chest physiotherapy affects lung function in people with primary ciliary dyskinesia (a lifelong condition affecting mucus movement in the lungs). It may help care teams understand which breathing therapies work best and how your lungs respond.
This trial tests whether inhaling a saltwater solution (hypertonic saline) twice a day for 12 weeks can help people with bronchiectasis who have a chronic cough and have had flare-ups in the past. It aims to see if this treatment reduces mucus and improves quality of life.
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Hear when a new Primary Ciliary Dyskinesia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.